CVS Health (CVS) Q3 2025 10-Q Quarterly Report
Filed: Oct 29, 2025Period ending Sep 30, 2025
Consumer Discretionary
Retail-Drug Stores and Proprietary StoresSEC EDGAR CVS Health (CVS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 29, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
CVS Health Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • No financial data or segment performance disclosed in the provided MD&A excerpt
- • Forward-looking statements caution under Reform Act, no updated guidance or outlook given
Risk Factors
- • No material changes to risk factors compared to 10-K, risks carried forward without update
- • COVID-19 pandemic impact on operations and supply chain remains significant near-term operational risk
CVS Health Q3 2025 Quarterly FinancialsXBRL
Revenue
$102.9B
▲ +7.8% YoY▲ +4.0% QoQ
Net Income
-$4.0B
▼ -4669.0% YoY▼ -489.3% QoQ
Operating Margin
-3.1%
▼ -399bp YoY▼ -552bp QoQ
Net Margin
-3.9%
▼ -396bp YoY▼ -490bp QoQ
ROE
-5.5%
Total Assets
$255.3B
EPS (Diluted)
$-3.14
▼ -4585.7% YoY▼ -492.5% QoQ
Operating Cash Flow
$796M
▲ +206.8% YoY▼ -58.0% QoQ
Source: XBRL data from CVS Health Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other CVS Health Quarterly Reports
Get deeper insights on CVS Health
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.